Larman, H. BenjaminLaserson, UriQuerol, LuisVerhaeghen, KatrijnSolimini, Nicole L.Xu, GeorgeKlarenbeek, Paul L.Church, GeorgeHafler, David A.Plenge, Robert M.Nigrovic, PeterDe Jager, PhilipWeets, IlseMartens, Geert A.O'Connor, Kevin C.Elledge, Stephen2022-07-212013-06Larman, H. Benjamin, Uri Laserson, Luis Querol, Katrijn Verhaeghen, Nicole L. Solimini, George Xu, Paul L. Klarenbeek et al. "PhIP-Seq Characterization of Autoantibodies From Patients With Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis." Journal of Autoimmunity 43 (2013): 1-9. DOI: 10.1016/j.jaut.2013.01.0130896-8411https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37372752Autoimmune disease results from a loss of tolerance to self-antigens in genetically susceptible individuals. Completely understanding this process requires that targeted antigens be identified, and so a number of techniques have been developed to determine immune receptor specificities. We previously reported the construction of a phage-displayed synthetic human peptidome and a proof-of-principle analysis of antibodies from three patients with neurological autoimmunity. Here we present data from a large-scale screen of 298 independent antibody repertoires, including those from 73 healthy sera, using phage immunoprecipitation sequencing. The resulting database of peptide-antibody interactions characterizes each individual’s unique autoantibody fingerprint, and includes specificities found to occur frequently in the general population as well as those associated with disease. Screening type 1 diabetes (T1D) patients revealed a prematurely polyautoreactive phenotype compared with their matched controls. A collection of cerebrospinal fluids and sera from 63 multiple sclerosis patients uncovered novel, as well as previously reported antibody-peptide interactions. Finally, a screen of synovial fluids and sera from 64 rheumatoid arthritis patients revealed novel disease-associated antibody specificities that were independent of seropositivity status. This work demonstrates the utility of performing PhIP-Seq screens on large numbers of individuals and is another step toward defining the full complement of autoimmunoreactivities in health and disease.en-USResearch Subject Categories::MEDICINE::Microbiology, immunology, infectious diseases::ImmunologyJournal Article2017-08-0720132022-07-2110.1016/j.jaut.2013.01.013